Skip to content
10-Q

Quarterly Report

KRAIG BIOCRAFT LABORATORIES, INC. KBLB

0001493152-26-023130

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 1.09B sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.04B sh
Capex Q1 2026 · Mar 31, 2026 $14.12K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$529.72K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$434.5K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.89M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.79M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$7.06M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$8M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$8.55M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$8.15M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.68M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $10.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.56M
Current Assets Q1 2026 · Mar 31, 2026 $3.01M
Current Assets Q1 2026 · Dec 31, 2025 $1.87M
Total Assets Q1 2026 · Mar 31, 2026 $3.72M
Total Assets Q1 2026 · Dec 31, 2025 $2.57M
Total Assets Q1 2026 · Mar 31, 2025 $1.32M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $495.57K
Sga Expense Q1 2026 · Mar 31, 2025 $308.85K
Rd Expense Q1 2026 · Mar 31, 2026 $66.7K
Rd Expense Q1 2026 · Mar 31, 2025 $23.88K
Net Income Q1 2026 · Mar 31, 2026 −$942.72K
Net Income Q1 2026 · Mar 31, 2025 −$600.03K
Operating Income Q1 2026 · Mar 31, 2026 −$825.5K
Operating Income Q1 2026 · Mar 31, 2025 −$580.49K